Melatonin influence on clinical and endocrine measures in early rheumatoid arthritis
https://doi.org/10.14412/1995-4484-2008-411
Abstract
Objective. To assess melatonin (ML) efficacy for correction of sleep disturbances, its influence on clinical symptoms and laboratory activity measures as well as cortisol level in pts with rheumatoid arthritis (RA) Material and methods. Blind randomized placebo controlled study was performed. 38 women with RA fulfilling ACR criteria and disease duration not exceeding a year were included. Pts of the main group (n=19) received melatonin (Melaxen, Unifarm, USA) 3 mg I hour before sleep, control group pts (n= 19) received placebo. All pts received nonsteroidal anti-inflammatory drugs and disease modifying anti-rheumatic drugs. Clinico-laboratory measures of inflammatory activity, sleepless symptoms score, plasma cortisol and urine 6-sulphotoximelanotonin (6-STM) levels with immuno-enzyme assay were evaluated. Results. To the end of study sleep quality improved and morning stiffness significantly decreased in the main group pts in comparison with placebo group. 20% decrease of morning stiffness was achieved in 90% of ML group and 44% of placebo group pts. Other clinical features of RA including DAS28 changes did not significantly differ between groups. Treatment with ML also induced endocrine status changes in RA pts: decrease of plasma cortisol and significant increase of urine 6-STM levels. Endocrine measures did not change in placebo group. Conclusion. ML efficacy in the treatment of sleep disturbances in pts with RA was confirmed. Decrease of cortisol blood level in such pts probably connected with shift of its peak to earlier hours providing decrease of morning stiffness.
References
1. <div><p>Мелатонин в норме и патологии. Под ред. Комарова Ф.И., Рапопорта С.И., Малиновской Н.К., Анисимова В.Н. М. 2004, 7-85, 182-194.</p><p>Левин Я. И. Мелатонин (Мелаксен) в терапии инсомнии. РМЖ, 2005, 13, 7, 498-501.</p><p>Drewes A.M., Svendsen L., Taagholt S.J. et al. Sleep in rheumatoid arthritis: a comparison with healthy subjects and studies of sleep/wake interactions. Br. J. Rheumatol., 1998, 37, 71-81.</p><p>Kapsimalis F., Richardson G., Opp M.R., Kryger M. Cytokines and normal sleep. Curr. Opin. Pulm. Med., 2005, 11(6), 481-484.</p><p>Reiter R.J., Tan D.X., Sainz R.M. et al. Melatonin: reducing the toxicity and increasing the efficacy of dmgs. J. Pharm. Pharmacol., 2002, 54(10), 12991321.</p><p>Reiter R.J., Melchioiri D., Sewetynek E. et al. A review of the evidence supporting melatonin’s role as an antioxidant. J. Pineal. Res., 1995, 18(1), 1-11.</p><p>Labrecque G., Bureau J.P., Reinberg A.E. Biological rhythms in the inflammatory response and in the effects of non-steroidal anti-inflammatory drugs. Phannac. Ther., 1995, 66, 285-300.</p><p>Harkness J.A.L., Richter M.B., Panayi G.S. et al. Circadian variations in disease activity in rheumatoid arthritis. BMJ, 1982, 284, 551-554.</p><p>Cutolo М., Villaggio В., Otsa К. et al. Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease’s symptoms. Autoimmun. Rev., 2005, 8, 497-502.</p><p>Каратеев A.E., Каратеев Д.Е., Лучихина Е.Л., Насонова В.А. Первый опыт применения мелатонина для коррекции нарушений сна у больных с ревматоидным артритом. Научно- практич. ревматол., 2004, 4, 73-76. П. Morrey К.М., McLachlan J.A., Serkin C.D., Bakouche О. Activation of human monocytes by the pineal hormone melatonin. J. Immunol., 1994, 153, 2671-2680.</p><p>Garcia-Maurino S., Gonzalez-Haba M.G., CalvoJ.R. et al. Melatonin enhances IL-2, 1L-6 and IFN-y production by human circulatingCD4+ cells. J. Immunol., 1997, 159, 574-581.</p><p>Sainz R.M., Mayo J.C., Reiter R.J. et al. Melatonin regulates glucocorticoid receptor: an answer to its antiapoptotic action in thymus. FASEB J., 1999, 13, 1547-1556.</p><p>Cantorna М. T. Vitamin D and autoimmunity: is vitamin D status an environmentalfactor affecting autoimmune disease prevalence? Proc. Soc. Exp. Biol. Med., 2000, 223, 230-233.</p><p>Rozin A., Balbir-Gurman A., Chapira D. Seasonal distribution of relapse onset in rheumatoid arthritis and spondyloarthropathy: the possible effect of solar factor. Clin. Exp. Rheumatol., 2003, 21, 161-169.</p><p>Cutolo M. Solar light effects on onset/releases and circanmial/circadian symptomatology in rheumatoid arthritis. Clin. Exp. Rheumatol., 2003, 21, 148-150.</p><p>Cutolo М., Maestroni G.J.M., Otsa K. et al. Circadian melatonin and cortisol levels in rheumatoid arthritis patients in winter time: a north and south Europe comparison. Ann. Rheum. Dis., 2005, 64, 212-216.</p><p>Giordano М., Palermo M.S. Melatonin-induced enhancement of antibody-dependent cellular cytotoxicity. J. Pineal. Res., 1991, 10, 117-121.</p><p>Liu F., Ng T.B., Fung M.C. Pineal indoles stimulate the gene expression of immunomodulating cytokines. J. Neural. Transm., 2001, 108, 397-405.</p><p>Carrillo-Vico A., Garcia-Mauriho S., Calvo J.R., Guerrero J.M. Melatonin counteracts the inhibitory effect of PGE2 on 1L-2 production in human lymphocytes via its mtl membrane receptor. FASEB J., 2003, 17, 755-757.</p><p>Barjavel M.J., Mamdouh Z., Raghbate N., Bakouche O. Differential expression of the melatonin receptor in human monocytes. J. Immunol., 1998, 160, 1191— 1197.</p><p>Forrest C.M., Mackay G.M., Stoy N. et al. Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Br. J. Clin. Pharmacol., 2007, 64(4), 517-526.</p></div><br />
Review
For citations:
Pogozeva E.Y., Karateev A.E., Karateev D.E., Alexandrova E.N., Novikov A.A., Nasonova V.A. Melatonin influence on clinical and endocrine measures in early rheumatoid arthritis. Rheumatology Science and Practice. 2008;46(5):26-31. (In Russ.) https://doi.org/10.14412/1995-4484-2008-411
Views:
2164
Email this article 